Physician profile
Mark Roger Buboltz
NPI 1205249620
$6,435.97
in general payments reported to CMS, 2019-2025
18 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 92% of Corneal and Contact Management providers received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,030 · 2020: $43.00 · 2021: $330 · 2022: $920 · 2023: $867 · 2024: $345 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,456 · Food and Beverage: $1,307 · Gift: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,456.25 |
| Food and Beverage | $1,306.51 |
| Gift | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,185.39 | 2023-2025 | Lumigan, Vuity, Alphagan P |
| Alcon Vision LLC | $1,051.10 | 2019-2025 | Tryptyr, Argos |
| Eyevance Pharmaceuticals LLC | $1,000.00 | 2019 | |
| Glaukos Corporation | $880.10 | 2022-2025 | Kxl System, Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem |
| Oyster Point Pharma, INC. | $803.22 | 2022-2025 | Tyrvaya, Ryzumvi |
| Visionary Optics LLC | $350.00 | 2023 | |
| Dompe US, INC. | $256.30 | 2019-2025 | Oxervate |
| Biotissue Holdings INC. | $210.55 | 2023-2025 | |
| Carl Zeiss Meditec USA, INC. | $158.85 | 2025 | Cirrus Hd-Oct |
| Sight Sciences, INC. | $149.50 | 2021 | |
| Sun Pharmaceutical Industries INC. | $95.52 | 2019-2025 | |
| Synergeyes, INC. | $84.21 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $58.31 | 2019-2022 | |
| Ocular Therapeutix, INC. | $50.00 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $37.92 | 2025 | Amo Phaco Needle |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $29.98 | 2021 | |
| The Cameron-Ehlen Group, INC. | $20.65 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $14.37 | 2025 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Buboltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.